Inotek Pharmaceuticals Corporation Will Host Its First R&D Day

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) will host its first R&D Day next month.
According to the press release:

[Inotek,] a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that it will host its first R&D Day on Thursday, December 17, 2015, from 10:00 a.m. to 1:30 p.m. EST in New York City. Members of the Inotek management team and distinguished guest speakers will provide an overview of glaucoma and other optic nerve neuropathies, and the Company’s lead product candidate, trabodenoson, a first-in-class selective adenosine mimetic currently in Phase 3 development.

 
Click here to read the full press release.